Abstract
Modern schemes of the recurrences predicting after surgical treatment of benign tumors of mammary gland (BTMG) were estimated. In accordance to data of retrospective investigation obtained, the recurrences occurrence rate through a five-year period of observation have constituted 2.3%. While doing prospective observation, the recurrences after treatment have occurred in 12 (24.0%) patients, suffering phylloid histologic form of tumor. The BTMG recurrences were noted predominantly in women--carriers of mutant alleles with polymorphism rs8190924 of gene GSR and AA rs3763511--of gene DKK4. Nethertheless, there are no data, which confirm the recurrence occurrence risk to be considered genetically determinated, the possibilities ratio for this kind of polymorphism have costituted 12.0 (trustworthy interval 95% 0.8 - 14.9).
MeSH terms
-
Adult
-
Breast Neoplasms / diagnosis*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / pathology
-
Breast Neoplasms / surgery
-
Female
-
Fibroadenoma / diagnosis*
-
Fibroadenoma / genetics
-
Fibroadenoma / pathology
-
Fibroadenoma / surgery
-
Gene Expression
-
Glutathione Reductase / genetics*
-
Heterozygote
-
Homozygote
-
Humans
-
Intercellular Signaling Peptides and Proteins / genetics*
-
Mammary Glands, Human / pathology
-
Mammary Glands, Human / surgery
-
Neoplasm Recurrence, Local / diagnosis*
-
Neoplasm Recurrence, Local / genetics
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Recurrence, Local / surgery
-
Neoplasms / diagnosis*
-
Neoplasms / genetics
-
Neoplasms / pathology
-
Neoplasms / surgery
-
Odds Ratio
-
Polymorphism, Genetic
-
Prognosis
-
Prospective Studies
-
Risk Factors
Substances
-
DKK4 protein, human
-
Intercellular Signaling Peptides and Proteins
-
Glutathione Reductase